How does ferroptosis induction by ailanthone connect to the HIF-1α/LINC01956 pathway?

The abstract states ailanthone decreases GBM growth via ferroptosis induction and also via the HIF-1α/LINC01956 pathway, but doesn’t explain if these are independent mechanisms or how they interconnect. Clarifying this relationship is important for understanding the drug’s complete mechanism of action.

Gap type: unexplained_observation Source paper: Ailanthone disturbs cross-talk between cancer cells and tumor-associated macrophages via HIF1-α/LINC01956/FUS/β-catenin signaling pathway in glioblastoma. (None, None, PMID:39639311)

Ailanthone is a quassinoid natural compound derived from Ailanthus altissima with established broad anti-tumor activity. Recent work has demonstrated two distinct mechanisms of ailanthone action in glioblastoma multiforme (GBM): ferroptosis induction—an iron-dependent form of regulated cell death characterized by lipid peroxide accumulation and GPX4 depletion—and suppression of the HIF-1α/LINC01956 signaling axis (Ailanthone: a multi-targeting quassinoid for broad-spectrum therapeutic applications, Journal of Ethnopharmacology 2026). The HIF-1α/LINC01956 pathway is a hypoxia-responsive axis in which HIF-1α, stabilized under the hypoxic GBM tumor microenvironment, drives lncRNA LINC01956 expression, which in turn supports tumorigenic gene programs. Ailanthone has also been shown to disrupt cross-talk between GBM cells and tumor-associated macrophages, adding a third immune microenvironment dimension (Ailanthone disturbs cancer cell-macrophage cross-talk, Cancer Cell International 2024).

The core mechanistic gap is whether ferroptosis induction and HIF-1α/LINC01956 suppression are parallel, independent mechanisms or causally linked. Ferroptosis sensitivity is regulated by HIF-1α targets including transferrin receptor (TFRC), which increases iron uptake, and HIF-1α’s modulation of lipid metabolism genes—suggesting that HIF-1α suppression by ailanthone could independently sensitize cells to ferroptosis by altering iron and lipid homeostasis. Conversely, LINC01956 might regulate GPX4 or SLC7A11 expression (key ferroptosis suppressors), making the lncRNA a mechanistic node upstream of ferroptosis. Alternatively, both pathways may be downstream of a common ailanthone target—perhaps NF-κB or the proteasome—that simultaneously destabilizes HIF-1α and depletes GPX4.

Resolving this gap requires pathway epistasis experiments: LINC01956 overexpression rescue studies in ailanthone-treated GBM cells to assess whether restored lncRNA expression rescues ferroptosis resistance; GPX4 activity assays and lipid peroxidation measurements in HIF-1α-knockdown vs. HIF-1α-overexpressing GBM lines treated with ailanthone; and concurrent metabolomic profiling of glutathione and iron pools. Such studies would establish a mechanistic hierarchy and inform whether rational combinations targeting HIF-1α and ferroptosis would be additive or redundant in GBM treatment.